Authored By: Sarah
11 Jul 2024

 Allergy Immunotherapies Market Size to grow by USD 1189 million between 2024-2028

According to a research report “ Allergy Immunotherapies Market” by Product (SCIT, SLIT) Type (Allergic Rhinitis, Asthma, Food Allergy, Others) Geography (Europe, North America, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 1189 million, at a CAGR of almost 9.62% during the forecast period. The global allergy market is experiencing substantial growth due to the increasing prevalence of allergies, with an estimated 500 million people affected. Factors such as pollution and tobacco consumption are significant contributors to this trend. Although some individuals may develop immunity or resistance to allergens over time, the majority of allergy cases are chronic and recurring. Consequently, the allergy immunotherapies market is poised for significant expansion during the forecast period, as a large segment of the population continues to require treatment for their allergies.

Browse market data tables, figures, and in-depth TOC on “Allergy Immunotherapies Market” by Product (SCIT, SLIT) Type (Allergic Rhinitis, Asthma, Food Allergy, Others) Geography (Europe, North America, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample

 

By Product, the SCIT segment is projected to dominate the market size in 2024

The Allergy Immunotherapies Market represents a significant business opportunity due to the increasing prevalence of allergic disorders worldwide. Key players in this sector are investing in research and development to introduce innovative treatments, such as sublingual and subcutaneous immunotherapies, to cater to the growing demand. The market is expected to expand at a robust CAGR, driven by rising awareness, favorable regulatory policies, and increasing healthcare expenditures.

By Type, Allergic Rhinitis  segment is expected to hold the largest market size for the year 2024

The Allergy Immunotherapies Market represents a significant business opportunity due to the rising prevalence of allergic disorders worldwide. Key players in this sector are developing innovative treatments, such as sublingual tablets and allergen injection therapies, to cater to the growing demand for effective and convenient allergy management solutions. Market growth is further fueled by increasing healthcare expenditures and favorable regulatory environments. Overall, the Allergy Immunotherapies Market is poised for robust expansion in the coming years.

Europe is forecasted to hold the largest market size by region in 2024

The Allergy Immunotherapies Market represents a significant business opportunity for pharmaceutical companies, driven by the growing prevalence of allergic disorders worldwide. These therapies offer long-term relief for allergic conditions, making them an attractive alternative to traditional medication. Key players in this market are investing in research and development to expand their product portfolios and gain a competitive edge. Allergen immunotherapy, sublingual tablets, and allergy vaccines are among the major product categories driving market growth. The market is expected to witness robust expansion due to increasing awareness and diagnostic accuracy, favorable reimbursement policies, and rising disposable income.

The Allergy Immunotherapies Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • Adamis Pharmaceuticals Corp.
  • Aimmune Therapeutics Inc.
  • ALK Abello AS
  • ALLERGOPHARMA GmbH and Co. KG
  • Allergy Therapeutics PLC 
  • Biomay AG
  • DBV Technologies SA
  • Desentum Oy
  • HAL Allergy BV
  • Immunomic Therapeutics Inc.
  • Jubilant Pharmova Ltd.
  • LETI Pharma SLU
  • LOFARMA Spa
  • Merck KGaA
  • Novartis AG
  • Optum Inc.
  • SHIONOGI Co. Ltd.
  • Stallergenes Greer Ltd.
  • Torii Pharmaceutical Co. Ltd.
  • Viatris Inc.
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

The Allergy Immunotherapies Market encompasses a range of treatments for allergy illnesses, including those caused by pollen and other environmental triggers that affect the respiratory system. Allergy medicines have become increasingly important in the healthcare system due to the high prevalence of allergies and allergic reactions, exacerbated by factors like air pollution. Immunology and biotechnology have played a significant role in the development of personalized medicine for allergies, with biologics targeting the immune system to treat conditions like asthma and cancer. Key players in the market include Aimmune Therapeutics with their peanut allergy treatment, Palforzia, and Stallergenes Greer, offering allergy shots and SLIT (Sublingual Immunotherapy) for various allergens. SCIT (Subcutaneous Immunotherapy) is another common form of allergy immunotherapy. The market is witnessing growth in emerging economies due to increasing awareness and healthcare professionals' recommendations. However, challenges remain, including the high cost of these treatments and the need for consistent patient compliance.

Market Research Overview

Allergy illnesses, including food allergies and skin allergies such as atopic dermatitis, allergic rhinitis, conjunctivitis, and asthma, affect millions of people worldwide. Allergy immunotherapies, including Sublingual Immunotherapy (SLIT) and Subcutaneous Immunotherapy (SCIT), play a crucial role in managing these conditions. SLIT involves the administration of allergens in the form of tablets or drops under the tongue, while SCIT involves regular injections of allergens. Food allergies, triggered by consumption of specific foods, are a significant concern. Pollen, dust, and air pollution are common triggers for respiratory system allergies. Macroeconomic factors, including alcohol consumption and eating habits, also influence the prevalence of allergies. Allergy Therapeutics, Merck KGaA (Allergopharma), Leti Pharma, Hollister Allergy, Aimmune Therapeutics, and Stallergenes Greer are some of the leading allergy immunotherapy companies. They offer various products, including Alustal, Allergy shot, SLIT, and SCIT. Precision medicine and personalized medicine approaches, using diagnostic tools, biomarkers, and molecular mechanisms, are revolutionizing allergy immunotherapies. Gene therapies are also emerging as potential treatments for allergies and other immune system disorders. Healthcare systems and physicians play a vital role in the diagnosis and treatment of allergy illnesses. The use of immunology and biotechnology is essential in understanding the molecular mechanisms of allergic reactions and developing effective therapies. Emerging economies offer significant growth opportunities for allergy immunotherapy companies, with a large and growing population suffering from allergy illnesses. However, access to these treatments remains a challenge in many parts of the world. In conclusion, allergy immunotherapies, including SLIT and SCIT, are essential in managing various allergy illnesses. The role of healthcare professionals, precision medicine, and emerging companies is crucial in addressing the growing prevalence of allergies and improving access to effective treatments.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio